Gülhan, M. Et Al. 2022. Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing.. Revista da Associacao Medica Brasileira (1992) , vol.68, no.3 , 318-322.

Gülhan, M., Önal, U., Demirci, N., Cetin, G., Calisir, A., Köksalan, D., ... Solmaz, K.(2022). Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing.. Revista da Associacao Medica Brasileira (1992) , vol.68, no.3, 318-322.

Gülhan, Muhammet Et Al. "Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing.," Revista da Associacao Medica Brasileira (1992) , vol.68, no.3, 318-322, 2022

Gülhan, Muhammet Et Al. "Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing.." Revista da Associacao Medica Brasileira (1992) , vol.68, no.3, pp.318-322, 2022

Gülhan, M. Et Al. (2022) . "Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing.." Revista da Associacao Medica Brasileira (1992) , vol.68, no.3, pp.318-322.

@article{article, author={Muhammet Gülhan Et Al. }, title={Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing.}, journal={Revista da Associacao Medica Brasileira (1992)}, year=2022, pages={318-322} }